U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT06873516) titled 'A Randomized Dose-ranging Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)' on March 07.
Brief Summary: This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Spontaneous Urticaria
Intervention:
DRUG: EVO756
Dose 1
DRUG: EVO756
Dose 2
DRUG: EVO756
Dose 3
DRUG: Placebo control
Placebo control
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Evommune, Inc.
Published by HT Digital Content Services with permission fro...